HC Wainwright Reiterates "Buy" Rating for Alto Neuroscience (NYSE:ANRO)

HC Wainwright restated their buy rating on shares of Alto Neuroscience (NYSE:ANRO - Free Report) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

A number of other research firms also recently commented on ANRO. William Blair reiterated an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Wedbush reiterated a "neutral" rating and set a $4.00 target price on shares of Alto Neuroscience in a research report on Thursday, May 15th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $8.50.

Alto Neuroscience Price Performance

ANRO traded up $0.05 during trading on Thursday, reaching $2.35. 2,612,074 shares of the company traded hands, compared to its average volume of 408,894. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.53 and a current ratio of 22.53. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $17.55. The firm has a fifty day simple moving average of $2.47 and a 200 day simple moving average of $3.09. The company has a market cap of $63.48 million, a P/E ratio of -1.00 and a beta of 1.93.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06. On average, equities analysts forecast that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

A number of large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its stake in Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock worth $46,000 after acquiring an additional 3,139 shares during the period. Deutsche Bank AG increased its holdings in Alto Neuroscience by 31.3% in the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock worth $64,000 after buying an additional 3,629 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new position in Alto Neuroscience in the 4th quarter worth approximately $74,000. Jane Street Group LLC increased its holdings in Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after buying an additional 7,783 shares during the period. Finally, AQR Capital Management LLC acquired a new position in Alto Neuroscience in the 1st quarter worth approximately $52,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.